Swati Bhattacharyya

Dr. Swati Bhattacharyya

University of Michigan, Ann Arbor, MI, USA
orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 April 2022 in Seminars in Cell & Developmental Biology
Verified
Journal Article
Closed access
Swati BhattacharyyaSwati Bhattacharyya
Swati Bhattacharyya
KMKim S. Midwood
Kim S. Midwood
JVJohn Varga
John Varga

8 March 2022 in JCI Insight
Verified
Journal Article
Open access
PDF file
DXDan Xu
Dan Xu
Swati BhattacharyyaSwati Bhattacharyya
Swati Bhattacharyya
WWWenxia Wang
Wenxia Wang
Igal IferganIgal Ifergan
Igal Ifergan
MWMing-Yi Alice Chiang Wong
Ming-Yi Alice Chiang Wong
JVJohn Varga
John Varga
Systemic sclerosis (SSc) is a chronic, multisystem orphan disease with a highly variable clinical course, high mortality rate, and a poorly understood complex pathogenesis. We have identified an important role for a subpopulation of monocytes and macrophages characterized by surface expression of the scavenger receptor macrophage receptor with collagenous structure (MARCO) in chronic inflammation and fibrosis in SSc and in preclinical disease models. We show that MARCO + monocytes and macrophages accumulate in lesional skin and lung in topographic proximity to activated myofibroblasts in patients with SSc and in the bleomycin-induced mouse model of SSc. Short-term treatment of mice with a potentially novel nanoparticle, poly(lactic- co -glycolic) acid (PLG), which is composed of a carboxylated, FDA-approved, biodegradable polymer and modulates activation and trafficking of MARCO + inflammatory monocytes, markedly attenuated bleomycin-induced skin and lung inflammation and fibrosis. Mechanistically, in isolated cells in culture, PLG nanoparticles inhibited TGF-dependent fibrotic responses in vitro. Thus, MARCO + monocytes are potent effector cells of skin and lung fibrosis and can be therapeutically targeted in SSc using PLG nanoparticles.

26 October 2022 in Nature Communications
Verified
Journal Article
Open access
PDF file
WWWenxia Wang
Wenxia Wang
SBSwarna Bale
Swarna Bale
JWJun Wei
Jun Wei
BYBharath Yalavarthi
Bharath Yalavarthi
DBDibyendu Bhattacharyya
Dibyendu Bhattacharyya
JVJohn Varga
John Varga
In addition to autoimmune and inflammatory diseases, variants of the TNFAIP3 gene encoding the ubiquitin-editing enzyme A20 are also associated with fibrosis in systemic sclerosis (SSc). However, it remains unclear how genetic factors contribute to SSc pathogenesis, and which cell types drive the disease due to SSc-specific genetic alterations. We therefore characterize the expression, function, and role of A20, and its negative transcriptional regulator DREAM, in patients with SSc and disease models. Levels of A20 are significantly reduced in SSc skin and lungs, while DREAM is elevated. In isolated fibroblasts, A20 mitigates ex vivo profibrotic responses. Mice haploinsufficient for A20, or harboring fibroblasts-specific A20 deletion, recapitulate major pathological features of SSc, whereas DREAM-null mice with elevated A20 expression are protected. In DREAM-null fibroblasts, TGF-β induces the expression of A20, compared to wild-type fibroblasts. An anti-fibrotic small molecule targeting cellular adiponectin receptors stimulates A20 expression in vitro in wild-type but not A20-deficient fibroblasts and in bleomycin-treated mice. Thus, A20 has a novel cell-intrinsic function in restraining fibroblast activation, and together with DREAM, constitutes a critical regulatory network governing the fibrotic process in SSc. A20 and DREAM represent novel druggable targets for fibrosis therapy.

1 January 2021 in AIMS Allergy and Immunology
Verified
Journal Article
Open access
PDF file
SBSwarna Bale
Swarna Bale
JVJohn Varga
John Varga
Swati BhattacharyyaSwati Bhattacharyya
Swati Bhattacharyya
Toll-like receptors (TLRs) are essential defensive mediators implicated in immune diseases. Tight regulation of TLR function is indispensable to avoid the damaging effects of chronic signaling. Several endogenous molecules have emerged as negative regulators of TLR signaling. In this review, we highlighted the structure, regulation, and function of RP105 and A20 in negatively modulating TLR-dependent inflammatory diseases, and in fibrosis and potential therapeutic approaches.

1 January 2025 in American Journal of Respiratory and Critical Care Medicine
Verified
Journal Article
Open access
PVPriyanka Verma
Priyanka Verma
THTimothy Hamill
Timothy Hamill
Swati BhattacharyyaSwati Bhattacharyya
Swati Bhattacharyya

31 January 2023 in Nature Communications
Verified
Journal Article
Open access
PDF file
WWWenxia Wang
Wenxia Wang
SBSwarna Bale
Swarna Bale
JWJun Wei
Jun Wei
BYBharath Yalavarthi
Bharath Yalavarthi
DBDibyendu Bhattacharyya
Dibyendu Bhattacharyya
JVJohn Varga
John Varga